Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

rowex ltd - emtricitabine; tenofovir disoproxil - film-coated tablet - 200 mg/245 milligram(s) - antivirals for treatment of hiv infections, combinations; tenofovir disoproxil and emtricitabine

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - emtricitabine; tenofovir disoproxil - film-coated tablet - 200 mg/245 milligram(s) - antivirals for treatment of hiv infections, combinations; tenofovir disoproxil and emtricitabine

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

teva b.v. - emtricitabine; tenofovir disoproxil - film-coated tablet - 200 mg/245 milligram(s) - antivirals for treatment of hiv infections, combinations; tenofovir disoproxil and emtricitabine

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - emtricitabine; tenofovir disoproxil - film-coated tablet - 200 mg/245 milligram(s) - antivirals for treatment of hiv infections, combinations; tenofovir disoproxil and emtricitabine

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - emtricitabine; tenofovir disoproxil - film-coated tablet - 200 mg/245 milligram(s) - antivirals for treatment of hiv infections, combinations; tenofovir disoproxil and emtricitabine

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

tillomed pharma gmbh - emtricitabine; tenofovir disoproxil fumarate - film-coated tablet - 200/245 milligram(s) - antivirals for treatment of hiv infections, combinations; tenofovir disoproxil and emtricitabine

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

state of florida doh central pharmacy - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s) - emtricitabine 200 mg - emtriva® is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. additional important information regarding the use of emtriva for the treatment of hiv-1 infection: - emtriva should not be coadministered with atripla® , truvada® , or lamivudine-containing products [see warnings and precautions (5.3)]. - in treatment-experienced patients, the use of emtriva should be guided by laboratory testing and treatment history [see clinical pharmacology (12.4)]. emtriva is contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the products. pregnancy category b the incidence of fetal variations and malformations was not increased in embryofetal toxicity studies performed with emtricitabine in mice at exposures (auc) approximately 60-fold higher and in rabbits at approximately 120-fold higher than human exposures at the recommended daily dose. there are, however, no adequate and well-controlled studies in pregnant women. because an

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

excella gmbh - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s) - emtricitabine 200 mg - emtriva® is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. additional important information regarding the use of emtriva for the treatment of hiv-1 infection: - emtriva should not be coadministered with atripla® , truvada® , or lamivudine-containing products [see warnings and precautions (5.3)]. - in treatment-experienced patients, the use of emtriva should be guided by laboratory testing and treatment history [see clinical pharmacology (12.4)]. emtriva is contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the products. pregnancy category b the incidence of fetal variations and malformations was not increased in embryofetal toxicity studies performed with emtricitabine in mice at exposures (auc) approximately 60-fold higher and in rabbits at approximately 120-fold higher than human exposures at the recommended daily dose. there are, however, no adequate and well-controlled studies in pregnant women. because an

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

physicians total care, inc. - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s) - emtricitabine 200 mg - emtriva® is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. additional important information regarding the use of emtriva for the treatment of hiv-1 infection: - emtriva should not be coadministered with atripla® , complera™, truvada® , or lamivudine-containing products [see warnings and precautions (5.3)]. - in treatment-experienced patients, the use of emtriva should be guided by laboratory testing and treatment history [see clinical pharmacology (12.4)]. emtriva is contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the products. pregnancy category b the incidence of fetal variations and malformations was not increased in embryofetal toxicity studies performed with emtricitabine in mice at exposures (auc) approximately 60-fold higher and in rabbits at approximately 120-fold higher than human exposures at the recommended daily dose. there are, however, no adequate and well-controlled studies in pregnant women

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - emtricitabine, quantity: 200 mg; tenofovir disoproxil maleate, quantity: 300 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; iron oxide red; microcrystalline cellulose; hyprolose; titanium dioxide; hypromellose; triacetin; iron oxide yellow; brilliant blue fcf aluminium lake - treatment of hiv-1 infection: tenofovir disoproxil emtricitabine mylan 300/200 is indicated for the treatment of hiv infected adults over the age of 18 years, in combination with other antiretroviral agents. pre-exposure prophylaxis: tenofovir disoproxil emtricitabine mylan 300/200 is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults at high risk. this indication is based on clinical trials in men who have sex with men (msm) at high risk for hiv-1 infection and in heterosexual serodiscordant couples (see clinical studies).